Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2020-10-28
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of bortezomib when given with
rituximab and chemotherapy drugs and to see how well they work in treating participants with
mantle cell lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the
enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with
the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as
cyclophosphamide, doxorubicin, vincristine, dexamethasone, methotrexate, and cytarabine, work
in different ways to stop the growth of cancer cells, either by killing the cells, by
stopping them from dividing, or by stopping them from spreading. Giving bortezomib, rituximab
and combination chemotherapy may work better at treating mantle cell lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)